Annexon Inc. (NASDAQ:ANNX) shares traded 9.44% higher at $6.84 on Wall Street last session.
In accordance with the data, 8 analysts cover Annexon Inc. (NASDAQ:ANNX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $30.00 and a low of $4.63, we find $15.00. Given the previous closing price of $6.25, this indicates a potential upside of 140.0 percent. ANNX stock price is now 27.56% away from the 50-day moving average and 47.07% away from the 200-day moving average. The market capitalization of the company currently stands at $297.68M.
It has been rated a hold by 0 analysts and a buy by 8. Brokers who have rated the stock have averaged $15.95 as their price target over the next twelve months.
With the price target of $12, Jefferies recently initiated with Buy rating for Annexon Inc. (NASDAQ: ANNX). On September 09, 2022, BTIG Research recently initiated its ‘Buy’ rating on the stock quoting a target price of $15, while ‘H.C. Wainwright’ rates the stock as ‘Buy’.
In other news, Satter Muneer A, Director bought 2,453,988 shares of the company’s stock on Jul 07. The stock was bought for $9,423,314 at an average price of $3.84. Upon completion of the transaction, the Director now directly owns 4,408,966 shares in the company, valued at $30.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 14, President & CEO Love Douglas bought 60,000 shares of the business’s stock. A total of $146,814 was incurred on buying the stock at an average price of $2.45. This leaves the insider owning 200,942 shares of the company worth $1.37 million. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ANNX stock. A new stake in Annexon Inc. shares was purchased by DRIEHAUS CAPITAL MANAGEMENT LLC during the first quarter worth $8,834,000. PURA VIDA INVESTMENTS, LLC invested $2,562,000 in shares of ANNX during the first quarter. In the first quarter, CANDRIAM S.C.A. acquired a new stake in Annexon Inc. valued at approximately $1,132,000. EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in ANNX for approximately $687,000. VALUES FIRST ADVISORS, INC. purchased a new stake in ANNX valued at around $148,000 in the second quarter.
Annexon Inc. (NASDAQ: ANNX) opened at $6.27 on Friday. During the past 12 months, Annexon Inc. has had a low of $2.06 and a high of $8.69. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 13.60, and a quick ratio of 13.60. The fifty day moving average price for ANNX is $5.40 and a two-hundred day moving average price translates $4.67 for the stock.
The latest earnings results from Annexon Inc. (NASDAQ: ANNX) was released for Sep, 2022.
Annexon Inc.(ANNX) Company Profile
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington’s disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.